{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:45:43Z","timestamp":1792197943303,"version":"4.4.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,24]]},"DOI":"10.7759\/cureus.60968","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T03:22:43Z","timestamp":1716520963000},"source":"Crossref","is-referenced-by-count":6,"title":["Mortality, Hepatic Decompensation, and Cardiovascular- and Renal-Related Outcomes in Lean Versus Non-lean Patients Hospitalized With Metabolic Dysfunction-Associated Steatohepatitis (MASH)"],"prefix":"10.7759","author":[{"given":"Chukwunonso","family":"Ezeani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chidiebele","family":"Omaliko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan A","family":"Al-Ajlouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basile","family":"Njei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes C","year":"2018","unstructured":"Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018, 67:123-33. 10.1002\/hep.29466","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella ME","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al.. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023, 77:1797-835. 10.1097\/HEP.0000000000000323","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-022-00814-z","article-title":"NAFLD in normal weight individuals","volume":"14","author":"DiStefano JK","year":"2022","unstructured":"DiStefano JK, Gerhard GS. NAFLD in normal weight individuals. Diabetol Metab Syndr. 2022, 14:45. 10.1186\/s13098-022-00814-z","journal-title":"Diabetol Metab Syndr"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i42.6514","article-title":"Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management","volume":"26","author":"Chrysavgis L","year":"2020","unstructured":"Chrysavgis L, Ztriva E, Protopapas A, Tziomalos K, Cholongitas E. Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management. World J Gastroenterol. 2020, 26:6514-28. 10.3748\/wjg.v26.i42.6514","journal-title":"World J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/cd18-0026","article-title":"Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality","volume":"37","author":"Golabi P","year":"2019","unstructured":"Golabi P, Paik J, Fukui N, Locklear CT, de Avilla L, Younossi ZM. Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality. Clin Diabetes. 2019, 37:65-72. 10.2337\/cd18-0026","journal-title":"Clin Diabetes"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17424","article-title":"Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities","volume":"57","author":"Wijarnpreecha K","year":"2023","unstructured":"Wijarnpreecha K, Li F, Lundin SK, et al.. Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities. Aliment Pharmacol Ther. 2023, 57:1014-27. 10.1111\/apt.17424","journal-title":"Aliment Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/nu13092928","article-title":"Independent dose-response associations between fetuin-A and lean nonalcoholic fatty liver disease","volume":"13","author":"Lu CW","year":"2021","unstructured":"Lu CW, Lee YC, Chiang CH, Chang HH, Yang WS, Huang KC. Independent dose-response associations between fetuin-A and lean nonalcoholic fatty liver disease. Nutrients. 2021, 13:10.3390\/nu13092928","journal-title":"Nutrients"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15763","article-title":"Gastrointestinal cancers in lean individuals with non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"44","author":"Souza M","year":"2024","unstructured":"Souza M, Diaz I, Barchetta I, Mantovani A. Gastrointestinal cancers in lean individuals with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Liver Int. 2024, 44:6-14. 10.1111\/liv.15763","journal-title":"Liver Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-2600876\/v1","article-title":"Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease [PREPRINT]","author":"Ishido S","year":"2023","unstructured":"Ishido S, Tamaki N, Takahashi Y, et al.. Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease [PREPRINT]. Res Sq. 2023, 10.21203\/rs.3.rs-2600876\/v1","journal-title":"Res Sq"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-2697995\/v1","article-title":"Lean indian patients with non-alcoholic fatty liver disease (NAFLD) have less metabolic risk factors but similar liver disease severity as non-lean patients with NAFLD [PREPRINT]","author":"De A","year":"2023","unstructured":"De A, Mehta M, Singh P, et al.. Lean indian patients with non-alcoholic fatty liver disease (NAFLD) have less metabolic risk factors but similar liver disease severity as non-lean patients with NAFLD [PREPRINT]. Res Sq. 2023, 10.21203\/rs.3.rs-2697995\/v1","journal-title":"Res Sq"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18178993","article-title":"Open issues in the transition from NAFLD to MAFLD: the experience of the Plinio study","volume":"18","author":"Baratta F","year":"2021","unstructured":"Baratta F, Ferro D, Pastori D, et al.. Open issues in the transition from NAFLD to MAFLD: the experience of the Plinio study. Int J Environ Res Public Health. 2021, 18:10.3390\/ijerph18178993","journal-title":"Int J Environ Res Public Health"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7120562","article-title":"Lean patients with non-alcoholic fatty liver disease have a severe histological phenotype similar to obese patients","volume":"7","author":"Denkmayr L","year":"2018","unstructured":"Denkmayr L, Feldman A, Stechemesser L, et al.. Lean patients with non-alcoholic fatty liver disease have a severe histological phenotype similar to obese patients. J Clin Med. 2018, 7:10.3390\/jcm7120562","journal-title":"J Clin Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000329","article-title":"Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study)","volume":"78","author":"Nabi O","year":"2023","unstructured":"Nabi O, Lapidus N, Boursier J, et al.. Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study). Hepatology. 2023, 78:272-83. 10.1097\/HEP.0000000000000329","journal-title":"Hepatology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16049","article-title":"Epidemiology and prevalence of lean nonalcoholic fatty liver disease and associated cirrhosis, hepatocellular carcinoma, and cardiovascular outcomes in the United States: a population-based study and review of literature","volume":"38","author":"Almomani A","year":"2023","unstructured":"Almomani A, Kumar P, Onwuzo S, et al.. Epidemiology and prevalence of lean nonalcoholic fatty liver disease and associated cirrhosis, hepatocellular carcinoma, and cardiovascular outcomes in the United States: a population-based study and review of literature. J Gastroenterol Hepatol. 2023, 38:269-73. 10.1111\/jgh.16049","journal-title":"J Gastroenterol Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.11.019","article-title":"Mortality and liver-related events in lean versus non-lean nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"21","author":"Ha J","year":"2023","unstructured":"Ha J, Yim SY, Karagozian R. Mortality and liver-related events in lean versus non-lean nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023, 21:2496-2507.e5. 10.1016\/j.cgh.2022.11.019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03351-5","article-title":"Long-term outcomes in lean and non-lean NAFLD patients: a systematic review and meta-analysis","author":"Huang S","year":"2023","unstructured":"Huang S, Bao Y, Zhang N, Niu R, Tian L. Long-term outcomes in lean and non-lean NAFLD patients: a systematic review and meta-analysis. Endocrine. 2023, 10.1007\/s12020-023-03351-5","journal-title":"Endocrine"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102569","article-title":"Cardiovascular morbidity and mortality in lean vs. non-lean MASLD: a comprehensive meta-analysis","volume":"49","author":"Nso N","year":"2024","unstructured":"Nso N, Mergen D, Ikram M, et al.. Cardiovascular morbidity and mortality in lean vs. non-lean MASLD: a comprehensive meta-analysis. Curr Probl Cardiol. 2024, 49:102569. 10.1016\/j.cpcardiol.2024.102569","journal-title":"Curr Probl Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.22037\/ghfbb.v15i3.2549","article-title":"Pathophysiological mechanisms of cardiovascular disorders in non-alcoholic fatty liver disease","volume":"15","author":"Garbuzenko DV","year":"2022","unstructured":"Garbuzenko DV. Pathophysiological mechanisms of cardiovascular disorders in non-alcoholic fatty liver disease. Gastroenterol Hepatol Bed Bench. 2022, 15:194-203. 10.22037\/ghfbb.v15i3.2549","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/life12081189","article-title":"New insights into non-alcoholic fatty liver disease and coronary artery disease: the liver-heart axis","volume":"12","author":"Cazac GD","year":"2022","unstructured":"Cazac GD, L\u0103c\u0103tu\u0219u CM, Mihai C, Grigorescu ED, Onofriescu A, Mihai BM. New insights into non-alcoholic fatty liver disease and coronary artery disease: the liver-heart axis. Life (Basel). 2022, 12:10.3390\/life12081189","journal-title":"Life (Basel)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1209625","article-title":"Editorial: the heart of NAFLD","volume":"10","author":"Chew NW","year":"2023","unstructured":"Chew NW, Kannan S, Chong B, Chin Y, Muthiah M. Editorial: the heart of NAFLD. Front Med (Lausanne). 2023, 10:1209625. 10.3389\/fmed.2023.1209625","journal-title":"Front Med (Lausanne)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00202","article-title":"Cardiovascular risk in fatty liver disease: the liver-heart axis-literature review","volume":"6","author":"Ismaiel A","year":"2019","unstructured":"Ismaiel A, Dumitra\u015fcu DL. Cardiovascular risk in fatty liver disease: the liver-heart axis-literature review. Front Med (Lausanne). 2019, 6:202. 10.3389\/fmed.2019.00202","journal-title":"Front Med (Lausanne)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2019.08.002","article-title":"Non-alcoholic fatty liver disease in lean individuals","volume":"1","author":"Albhaisi S","year":"2019","unstructured":"Albhaisi S, Chowdhury A, Sanyal AJ. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep. 2019, 1:329-41. 10.1016\/j.jhepr.2019.08.002","journal-title":"JHEP Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/257094-mortality-hepatic-decompensation-and-cardiovascular--and-renal-related-outcomes-in-lean-versus-non-lean-patients-hospitalized-with-metabolic-dysfunction-associated-steatohepatitis-mash","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T03:22:47Z","timestamp":1716520967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/257094-mortality-hepatic-decompensation-and-cardiovascular--and-renal-related-outcomes-in-lean-versus-non-lean-patients-hospitalized-with-metabolic-dysfunction-associated-steatohepatitis-mash"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.60968","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,24]]}}}